E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Claudiani, Simone; Apperley, Jane F; Gale, Robert Peter; Clark, Richard; Szydlo, Richard; Deplano, Simona; Palanicawandar, Renuka; Khorashad, Jamshid; Foroni, Letizia; Milojkovic, Dragana

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Claudiani, Simone; Apperley, Jane F; Gale, Robert Peter; Clark, Richard; Szydlo, Richard; Deplano, Simona; Palanicawandar, Renuka; Khorashad, Jamshid; Foroni, Letizia; Milojkovic, Dragana.

Afiliación

Claudiani S; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London Simone.Claudiani@imperial.nhs.uk.
Apperley JF; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London.
Gale RP; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London.
Clark R; Royal Liverpool University Hospital, UK.
Szydlo R; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London.
Deplano S; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London.
Palanicawandar R; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London.
Khorashad J; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London.
Foroni L; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London.
Milojkovic D; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London.

Haematologica ; 102(8): e297-e299, 2017 08.

Article en En | MEDLINE | ID: mdl-28495914

Asunto(s)

Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico; Inhibidores de Proteínas Quinasas/uso terapéutico; ARN Neoplásico; Privación de Tratamiento; Adulto; Anciano; Anciano de 80 o más Años; Femenino; Proteínas de Fusión bcr-abl/genética; Humanos; Leucemia Mielógena Crónica BCR-ABL Positiva/genética; Masculino; Persona de Mediana Edad; Proteínas Tirosina Quinasas; Inducción de Remisión

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: ARN Neoplásico / Leucemia Mielógena Crónica BCR-ABL Positiva / Privación de Tratamiento / Inhibidores de Proteínas Quinasas Tipo de estudio: Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google